Breast cancer-resistance protein expression using immunohistochemical staining and treatment by gefitinib for non-small cell lung cancer

Takefumi Oikawa, Tatsuo Ohira, Jitsuo Usuda, Yasuhiro Suga, Eiji Nakajima, Tkamoto Saijo, Masahiro Tsuboi, Takashi Hirano, Yoshikazu Sugimoto, Harubumi Kato

Research output: Contribution to journalArticle

Abstract

Objective. Somatic EGFR mutations correlate with hypersensitivity to gefitinib. However, there is a subset of cancer patients with EGFR mutations that do not respond well to gefitinib treatment. We examined breast cancer resistance protein (BCRP) expression and sensitivity to gefitinib. Materials and Methods. We studied 48 surgically resected non-small cell lung cancer (NSCLC) with postoperative recurrence. These patients were examined for BCRP expression immunohistochemically and mutations of EGFR exon18-21. Postoperative recurrence in cases treated with gefitinib and responses were assessed. Results. BCRP expression was detected in 7 of 48 (14.6%). EGFR mutations were detected in 17 of 48 (35.4%). In cases with EGFR mutation, there was only one case of no response, which was also found to have positive immunohistochemical staining for BCRP. Conclusion. Resistance to gefitinib by NSCLC with EGFR mutation may be recognized by BCRP expression.

Original languageEnglish
Pages (from-to)224-230
Number of pages7
JournalJournal of Tokyo Medical University
Volume66
Issue number2
Publication statusPublished - 2008 Apr

Fingerprint

Non-Small Cell Lung Carcinoma
Staining and Labeling
Breast Neoplasms
Mutation
Proteins
Therapeutics
Recurrence
gefitinib
Hypersensitivity
Neoplasms

Keywords

  • Acquired resistance
  • BCRP
  • EGFR
  • Gefitinib
  • Non-small cell lung cancer

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Breast cancer-resistance protein expression using immunohistochemical staining and treatment by gefitinib for non-small cell lung cancer. / Oikawa, Takefumi; Ohira, Tatsuo; Usuda, Jitsuo; Suga, Yasuhiro; Nakajima, Eiji; Saijo, Tkamoto; Tsuboi, Masahiro; Hirano, Takashi; Sugimoto, Yoshikazu; Kato, Harubumi.

In: Journal of Tokyo Medical University, Vol. 66, No. 2, 04.2008, p. 224-230.

Research output: Contribution to journalArticle

Oikawa, T, Ohira, T, Usuda, J, Suga, Y, Nakajima, E, Saijo, T, Tsuboi, M, Hirano, T, Sugimoto, Y & Kato, H 2008, 'Breast cancer-resistance protein expression using immunohistochemical staining and treatment by gefitinib for non-small cell lung cancer', Journal of Tokyo Medical University, vol. 66, no. 2, pp. 224-230.
Oikawa, Takefumi ; Ohira, Tatsuo ; Usuda, Jitsuo ; Suga, Yasuhiro ; Nakajima, Eiji ; Saijo, Tkamoto ; Tsuboi, Masahiro ; Hirano, Takashi ; Sugimoto, Yoshikazu ; Kato, Harubumi. / Breast cancer-resistance protein expression using immunohistochemical staining and treatment by gefitinib for non-small cell lung cancer. In: Journal of Tokyo Medical University. 2008 ; Vol. 66, No. 2. pp. 224-230.
@article{69492a05055b4c2b9a191f6d8f918b24,
title = "Breast cancer-resistance protein expression using immunohistochemical staining and treatment by gefitinib for non-small cell lung cancer",
abstract = "Objective. Somatic EGFR mutations correlate with hypersensitivity to gefitinib. However, there is a subset of cancer patients with EGFR mutations that do not respond well to gefitinib treatment. We examined breast cancer resistance protein (BCRP) expression and sensitivity to gefitinib. Materials and Methods. We studied 48 surgically resected non-small cell lung cancer (NSCLC) with postoperative recurrence. These patients were examined for BCRP expression immunohistochemically and mutations of EGFR exon18-21. Postoperative recurrence in cases treated with gefitinib and responses were assessed. Results. BCRP expression was detected in 7 of 48 (14.6{\%}). EGFR mutations were detected in 17 of 48 (35.4{\%}). In cases with EGFR mutation, there was only one case of no response, which was also found to have positive immunohistochemical staining for BCRP. Conclusion. Resistance to gefitinib by NSCLC with EGFR mutation may be recognized by BCRP expression.",
keywords = "Acquired resistance, BCRP, EGFR, Gefitinib, Non-small cell lung cancer",
author = "Takefumi Oikawa and Tatsuo Ohira and Jitsuo Usuda and Yasuhiro Suga and Eiji Nakajima and Tkamoto Saijo and Masahiro Tsuboi and Takashi Hirano and Yoshikazu Sugimoto and Harubumi Kato",
year = "2008",
month = "4",
language = "English",
volume = "66",
pages = "224--230",
journal = "Journal of Tokyo Medical University",
issn = "0040-8905",
publisher = "Medical Society of Tokyo Medical College",
number = "2",

}

TY - JOUR

T1 - Breast cancer-resistance protein expression using immunohistochemical staining and treatment by gefitinib for non-small cell lung cancer

AU - Oikawa, Takefumi

AU - Ohira, Tatsuo

AU - Usuda, Jitsuo

AU - Suga, Yasuhiro

AU - Nakajima, Eiji

AU - Saijo, Tkamoto

AU - Tsuboi, Masahiro

AU - Hirano, Takashi

AU - Sugimoto, Yoshikazu

AU - Kato, Harubumi

PY - 2008/4

Y1 - 2008/4

N2 - Objective. Somatic EGFR mutations correlate with hypersensitivity to gefitinib. However, there is a subset of cancer patients with EGFR mutations that do not respond well to gefitinib treatment. We examined breast cancer resistance protein (BCRP) expression and sensitivity to gefitinib. Materials and Methods. We studied 48 surgically resected non-small cell lung cancer (NSCLC) with postoperative recurrence. These patients were examined for BCRP expression immunohistochemically and mutations of EGFR exon18-21. Postoperative recurrence in cases treated with gefitinib and responses were assessed. Results. BCRP expression was detected in 7 of 48 (14.6%). EGFR mutations were detected in 17 of 48 (35.4%). In cases with EGFR mutation, there was only one case of no response, which was also found to have positive immunohistochemical staining for BCRP. Conclusion. Resistance to gefitinib by NSCLC with EGFR mutation may be recognized by BCRP expression.

AB - Objective. Somatic EGFR mutations correlate with hypersensitivity to gefitinib. However, there is a subset of cancer patients with EGFR mutations that do not respond well to gefitinib treatment. We examined breast cancer resistance protein (BCRP) expression and sensitivity to gefitinib. Materials and Methods. We studied 48 surgically resected non-small cell lung cancer (NSCLC) with postoperative recurrence. These patients were examined for BCRP expression immunohistochemically and mutations of EGFR exon18-21. Postoperative recurrence in cases treated with gefitinib and responses were assessed. Results. BCRP expression was detected in 7 of 48 (14.6%). EGFR mutations were detected in 17 of 48 (35.4%). In cases with EGFR mutation, there was only one case of no response, which was also found to have positive immunohistochemical staining for BCRP. Conclusion. Resistance to gefitinib by NSCLC with EGFR mutation may be recognized by BCRP expression.

KW - Acquired resistance

KW - BCRP

KW - EGFR

KW - Gefitinib

KW - Non-small cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=44449085022&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44449085022&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:44449085022

VL - 66

SP - 224

EP - 230

JO - Journal of Tokyo Medical University

JF - Journal of Tokyo Medical University

SN - 0040-8905

IS - 2

ER -